Acute atherothrombotic complications, as part of the accelerated atherosclerosis, contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in diabetic patients according to current scientific evidence.
Find related publications in this database (using NLM MeSH Indexing)